Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

NCT01026623 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

NIH

Sponsor class

Conditions

Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions

BIOLOGICAL: Cixutumumab
OTHER: Diagnostic Laboratory Biomarker Analysis
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)